Immunotherapy for acute lymphoblastic leukemia
Immunotherapy helps to strengthen or restore the immune system's ability to fight cancer. This works to kill cancer cells and stop cancer cells from growing and spreading.
Immunotherapy may be used to treat B-cell acute lymphoblastic leukemia (ALL). If you have immunotherapy, your healthcare team will use what they know about the cancer and about your health to plan the drugs, doses and schedules. Immunotherapy may be the only treatment you have or it may be used along with other treatments.
You may have immunotherapy to:
-
lower the risk that ALL will come back (recur or relapse)
- treat ALL that doesn't respond to other treatments (called refractory ALL) or recurs after treatment
Types of immunotherapy for ALL@(headingTag)>
Different types of immunotherapy can be used for B-cell ALL.
CAR T-cell therapy@(headingTag)>
CAR T-cell therapy takes millions of T cells from a person with cancer. In the lab, they are changed so they have chimeric antigen receptors (CARs) on their surface. These receptors recognize a specific antigen (protein) found on the type of cancer being treated. The T cells are then given back to the person where they multiply, attack and destroy the cancer cells.
Tisagenlecleucel (Kymriah) is a CAR T-cell therapy approved to treat young adults (up to and including age 25) with CD19-positive B-cell ALL that is refractory or has relapsed after stem cell transplant or other treatments. It may also be used to treat young adults with B-cell ALL who can't have a stem cell transplant.
This drug is given intravenously as a single dose in a one-time treatment. It is given at a specialized treatment centre.
Chemotherapy is given before you receive tisagenlecleucel.
Side effects of immunotherapy@(headingTag)>
Side effects of immunotherapy for ALL will depend mainly on the type of drug or drug combination, the dose, how it's given and your overall health. Tell your healthcare team if you have side effects that you think might be from immunotherapy. The sooner you tell them of any problems, the sooner they can suggest ways to help you deal with them.
The CAR T-cell therapy drug tisagenlecleucel can cause serious and life-threatening reactions such as CRS. This can occur days to weeks after you receive treatment. Symptoms can include high fever, chills, muscle aches and pain, joint stiffness, nausea and vomiting, sweating, and breathing problems. If you receive tisagenlecleucel, your healthcare team will check your blood counts regularly and watch for CRS, neurological problems and other side effects.
Other side effects can include:
-
infections
-
abdominal pain
-
constipation
-
weight loss
-
muscle cramps
-
emotional distress or anxiety
-
symptoms of high blood sugar such as thirst, low urine output, dark urine, dry flushed skin and irritability
- swelling of the arms or legs
Some people have serious reactions to immunotherapy drugs that are given intravenously. This is called an infusion reaction and may happen when the drug is going into your vein or soon after. If this happens, your healthcare team will give you medicines to reduce your side effects or stop your treatment to manage your reaction.
Find out more about immunotherapy@(headingTag)>
Find out more about immunotherapy. To make the decisions that are right for you, ask your healthcare team questions about immunotherapy.
Details about specific drugs change regularly. Find out more about sources of drug information and where to get details on specific drugs.
Your trusted source for accurate cancer information
With just $5 from readers like you, we can continue to provide the highest quality cancer information for over 100 types of cancer.
We’re here to ensure easy access to accurate cancer information for you and the millions of people who visit this website every year. But we can’t do it alone.
If everyone reading this gave just $5, we could achieve our goal this month to fund reliable cancer information, compassionate support services and the most promising research. Please give today because every contribution counts. Thank you.